Clinical Trial Update: A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion [Phase 2]

View source ↗

Summary

A Phase 2 trial of futibatinib (E7090) in unresectable or metastatic cholangiocarcinoma with FGFR2 gene fusion has completed. Sponsor: Eisai Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• E7090

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Cholangiocarcinoma | Phase 2 | Status: COMPLETED